SRHQ
SRH U.S. Quality ETF
SRHQ tracks an equally weighted index of US large-cap stocks screened based on three fundamental factors: value, growth, and quality.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 225.7 M
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Oct 05, 2022 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| QUALYS INC | 2.7 % |
| HUMANA INC | 2.6 % |
| COMMVAULT SYSTEMS INC | 2.3 % |
| CENTENE CORP | 2.2 % |
| BOX, INC. CLASS A | 2.0 % |
| ABERCROMBIE & FITCH CO-CL A | 1.9 % |
| INSPERITY INC | 1.9 % |
| NUTANIX, INC. CLASS A | 1.9 % |
| AMNEAL PHARMACEUTICALS, INC. CLASS A | 1.8 % |
| FRONTDOOR, INC. | 1.8 % |
Constituent Breakdown
| Number of holdings | 81 |
| Herfindahl-Hirschman Index | 135 |
| Wgt avg mkt cap (mns) | $33,972 |
| Large cap (>$10bn) | 55.0% |
| Mid cap ($2-10bn) | 42.8% |
| Small cap (<$2bn) | 1.9% |
| Developed mkts. | 99.9% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 99.9 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 17.4% | 20.3% | 11.2% | 17.5% | -- | -- | -- | 16.1% |
| Dividend Yield | 0.7% | 1.0% | 0.9% | 0.9% | -- | -- | -- | 1.0% |
| Total Returns | 18.1% | 21.3% | 12.1% | 18.4% | -- | -- | -- | 17.0% | Ann. Volatility | 14.8% | 14.7% | 16.6% | 15.7% | -- | -- | -- | 15.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.72 | 40% |
| MSCI EAFE | 0.49 | 29% |
| MSCI Emg Mkts | 0.20 | 11% |
Liquidity Measures
| Avg. volume (000) | 7 |
| ADV traded (mns) | $0 |
| Turnover | 0.2% |
| Avg. Bid/Ask (% of price) | 0.33% |
Technical Indicators
| 30d moving avg. (EMA) | $48.97 |
| Relative strength (RSI) | 59 |
| MACD/Signal | 0.60/0.47 |
| Bollinger Bands (Upper/Lower) | $51.04/$47.04 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. SRHQ |
Expenses vs. SRHQ |
ALTAR Score™ vs. SRHQ |
|---|---|---|---|---|
| DSTL | Distillate US Fundamental Stability & Value ETF | 18.4% | +4 bp | -0.1% |
| FCFY | First Trust S&P 500 Diversified Free Cash Flow ETF | 17.0% | +25 bp | +1.2% |
| LST | Leuthold Select Industries ETF | 16.6% | +50 bp | -1.8% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 15.6% | +5 bp | -2.5% |
| XHS | State Street SPDR S&P Health Care Services ETF | 14.9% | 0 bp | -6.0% |
| MCOW | Pacer S&P MidCap 400 Quality FCF Aristocrats ETF | 14.5% | +14 bp | -2.0% |
| RPV | Invesco S&P 500 Pure Value ETF | 13.9% | 0 bp | +1.1% |
| FXR | First Trust Industrials/Producer Durables AlphaDEX Fund | 13.8% | +25 bp | -0.7% |
| ONEV | State Street SPDR Russell 1000 Low Volatility Focus ETF | 12.8% | -15 bp | -0.7% |
| SMRI | Bushido Capital US Equity ETF | 12.5% | +36 bp | -0.2% |
Risk and Returns: SRHQ vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
8.7%
ALTAR SCORE™
93rd
PERCENTILE
SPECULATIVE
ETFRC RATING
There are 1,388 funds in the US Equity category with an average
ALTAR Score™ of 5.7% and a standard deviation
of 2.1%. SRHQ's ALTAR Score™ is approximately 1.5 standard
deviations above the category average. This places SRHQ in the 93rd percentile
among funds in the category.
Sell-Side Consensus
$56.92
PRICE TARGET
+12.3%
UPSIDE